First-ever TCL-AACI study of the leadership pipeline points to urgent need for more diversity at elite cancer centers – The Cancer Letter

publication date: Oct. 9, 2020By Matthew Bin Han Ong and Katie GoldbergHow diverse are the upper rungs of leadership at America’s academic cancer centers? Are these institutions promoting women and underrepresented minorities into top leadership positions? How prevalent are diversity recruitment programs? Do they work?Data on cancer center directors is more or less available, but a tally of…

Read the full article here

Source: cancerletter.com

Categories: Hem/Onc News and Journals, Latest Headlines

Tags: cancer

Tweets with this article

The Cancer Letter

First-ever TCL-@AACI_Cancer study of the leadership pipeline points to urgent need for more diversity at elite #cancer centers — https://t.co/38xxAT6Tbg [1/4] https://t.co/IT7dB22V2Y

Patient navigation benefits health systems, improves care Initial data presented at the White House come a year after CMS payment began – The Cancer Letter

One year after the Centers for Medicare & Medicaid Services made the decision to pay for patient navigation services, data from early adopters show that…

The Cancer Letter November 28, 2024

FDA accepts sNDA for prostate cancer treatment – The Cancer Letter

FDA has accepted Bayer’s supplemental new drug application for the oral androgen receptor inhibitor Nubeqa (darolutamide) in combination with androgen deprivation therapy for the treatment…

The Cancer Letter November 28, 2024

Exact Sciences data show multi-biomarker class approach improves MCED cancer detection – The Cancer Letter

Exact Sciences Corp. presented three abstracts highlighting advancements in the development of a multi-cancer early detection test at the American Association for Cancer Research Special…

The Cancer Letter November 28, 2024

As Trump’s second term nears, Republican support for NIH is at a low point By stonewalling GOP in the House, Biden’s HHS officials eroded bipartisan support for biomedical research – The Cancer Letter

The Biden administration has left NIH in a weakened state, intensifying politicization of science on Capitol Hill and eroding the bipartisan support the government’s premier…

The Cancer Letter November 28, 2024

Roy Herbst receives Ezra Greenspan Award from Chemotherapy+ Foundation – The Cancer Letter

Roy S. Herbst was awarded the Ezra Greenspan Award at the Innovation Gala of The Chemotherapy+ Foundation on Nov. 19 in New York City. To…

The Cancer Letter November 28, 2024

Phase III trial of subcutaneous pembrolizumab with berahyaluronidase alfa meets primary endpoints – The Cancer Letter

Merck announced positive topline results from the pivotal phase III MK-3475A-D77 trial. To access this subscriber-only content please log in or subscribe.If your institution has…

The Cancer Letter November 27, 2024

As Trump’s second term nears, Republican support for NIH is at a low point By stonewalling GOP in the House, Biden’s HHS officials eroded bipartisan support for biomedical research – The Cancer Letter

The Biden administration has left NIH in a weakened state, intensifying politicization of science on Capitol Hill and eroding the bipartisan support the government’s premier…

The Cancer Letter November 27, 2024

Patient navigation benefits health systems, improves care Initial data presented at the White House come a year after CMS payment began – The Cancer Letter

One year after the Centers for Medicare & Medicaid Services made the decision to pay for patient navigation services, data from early adopters show that…

The Cancer Letter November 27, 2024

William Oh named service medical director at Smilow Cancer Hospital at Greenwich – The Cancer Letter

William K. Oh was appointed as service medical director of Smilow Cancer Hospital at Greenwich Hospital, as well as director of precision medicine for Yale…

The Cancer Letter November 27, 2024

FDA approves Ziihera for HER2+ biliary tract cancer – The Cancer Letter

FDA accelerated approval of Ziihera (zanidatamab-hrii) 50mg/mL for injection for intravenous use for the treatment of adults with previously treated, unresectable or metastatic HER2-positive biliary…

The Cancer Letter November 27, 2024

Related Articles